Abstract Circulating tumor DNA (ctDNA, DNA shed by cancer cells) is emerging as one of
the most transformative cancer biomarkers discovered to-date. Although potentially useful at …

The majority of epidermal growth factor receptor (EGFR) mutations (85–90%) are exon 19
deletions and L858R point mutations of exon 21, characterized by high sensitivity to EGFR …

Epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) account
for≤ 12% of all EGFR‐mutant nonsmall cell lung cancers. We analysed real‐world datasets …

Smoking is a major risk factor for lung cancer, therefore lung cancer epidemiological trends
reflect the past trends of cigarette smoking to a great extent. The geographic patterns in …

Background The purpose of this analysis was to investigate the effectiveness of afatinib
compared to that of osimertinib in patients with non-small cell lung cancer (NSCLC) who …

Introduction Uncommon epidermal growth factor receptor (EGFR) mutations include single
and complex mutations. However, the association of the smoking status of patients with …

Objective To compare the therapeutic effects and adverse reactions of sterilizing rare earth
carbonate combined with concurrent chemoradiotherapy and simple concurrent …

In the realm of advanced non–small cell lung cancer (NSCLC) harboring epidermal growth
factor receptor (EGFR) therapy with tyrosine kinase inhibitors (TKI), addressing optimal …

Introduction The frequency of actionable mutations varies between races, and
Hispanic/Latino (H/L) people are a population with different proportions of ancestry. Our …

Starting with our previously reported work, a novel series of 3, 4-dihydro-2H-[1, 4] oxazino [2,
3-f] quinazolin-derivatives were designed, synthesized and evaluated as potent EGFR …